|
業務類別
|
-- |
|
業務概覽
|
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
| 公司地址
| Carl Jacobsens Vej 30, Valby, DNK, 2500 |
| 電話號碼
| +45 70202728 |
| 傳真號碼
| +45 70202729 |
| 公司網頁
| https://www.genmab.com |
| 員工數量
| 2819 |
| Mr. Rayne Waller |
Executive Vice President and Chief Technical Operations Officer |
DKK 1.70M |
17/02/2026 |
| Mr. Brad Bailey |
Executive Vice President and Chief Commercial Officer |
DKK 3.90M |
17/02/2026 |
| Dr. Jan G. J. van de Winkel, PhD |
President and Chief Executive Officer |
DKK 9.70M |
17/02/2026 |
| Dr. Judith Klimovsky, M.D. |
Executive Vice President and Chief Development Officer |
DKK 5.30M |
17/02/2026 |
| Dr. Mijke Zachariasse |
Director, Vice President and Head of Antibody Research Materials |
-- |
17/02/2026 |
| Dr. Tahamtan Ahmadi, PhD |
Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
DKK 5.00M |
17/02/2026 |
| Mr. Anthony Pagano |
Executive Vice President and Chief Financial Officer |
DKK 4.70M |
17/02/2026 |
| Dr. Martine J. van Vugt, PhD |
Executive Vice President and Chief Strategy Officer |
DKK 2.90M |
17/02/2026 |
| Mr. Greg Mueller |
Executive Vice President, General Counsel and Chief Legal Officer |
-- |
17/02/2026 |
| Mr. Christopher Cozic |
Executive Vice President and Chief People Officer |
DKK 3.40M |
17/02/2026 |
| Mr. Martin Schultz |
Director, Senior Director and Head of Development Business Partnership and Strategy |
-- |
17/02/2026 |
|
|
| Mr. Michael Kavanagh |
Director |
17/02/2026 |
| Ms. Deirdre P. Connelly |
Chairman of the Board |
17/02/2026 |
| Mr. Rolf Karl-Heinz Hoffmann |
Independent Director |
17/02/2026 |
| Mr. Anders Gersel Pedersen, M.D.,PhD |
Director |
17/02/2026 |
| Ms. Pernille Erenbjerg |
Deputy Chairman of the Board |
17/02/2026 |
| Dr. Paolo Paoletti, M.D. |
Independent Director |
17/02/2026 |
| Dr. Mijke Zachariasse |
Director, Vice President and Head of Antibody Research Materials |
17/02/2026 |
| Ms. Elizabeth G. O’Farrell |
Independent Director |
17/02/2026 |
| Mr. Martin Schultz |
Director, Senior Director and Head of Development Business Partnership and Strategy |
17/02/2026 |
|
|
|
|
